Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Other Accumulated Expenses of $3.6 billion for Q2 2026, little changed year-over-year from $3.6 billion in Q2 2025, and down 4.58% quarter-over-quarter from $3.8 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $3.6 billion for Q2 2026.
- In Q2 2026, Other Accumulated Expenses changed 0.5% year-over-year to $3.6 billion; the TTM figure through Jun 2026 stood at $3.6 billion (changed 0.5% YoY), while the FY2026 annual figure was $3.9 billion, changed 0.15% from the prior year.
- Other Accumulated Expenses for Q2 2026 stood at $3.6 billion, down from $3.8 billion in the prior quarter.
- The five-year high for Other Accumulated Expenses was $5.0 billion in Q1 2022, with the low at $3.3 billion in Q3 2024.
- The 5-year median for Other Accumulated Expenses is $3.9 billion (2023), against an average of $4.0 billion.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses declined 16.13% in 2024, then climbed 2.51% in 2025.
- Takeda Pharmaceutical's Other Accumulated Expenses stood at $4.5 billion in 2022, then slipped by 12.6% to $4.0 billion in 2023, then declined by 5.98% to $3.7 billion in 2024, then fell by 0.87% to $3.7 billion in 2025, then slipped by 2.69% to $3.6 billion in 2026.
- Business Quant data shows TAK's Other Accumulated Expenses at $3.6 billion in Q2 2026, $3.8 billion in Q1 2026, and $3.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.59 Bn |
| Mar 31, 2026 | 3.76 Bn |
| Dec 31, 2025 | 3.69 Bn |
| Sep 30, 2025 | 3.43 Bn |
| Jun 30, 2025 | 3.57 Bn |
| Mar 31, 2025 | 3.91 Bn |
| Dec 31, 2024 | 3.72 Bn |
| Sep 30, 2024 | 3.35 Bn |
| Jun 30, 2024 | 3.63 Bn |
| Mar 31, 2024 | 4.18 Bn |
| Dec 31, 2023 | 3.96 Bn |
| Sep 30, 2023 | 3.99 Bn |
| Jun 30, 2023 | 4.08 Bn |
| Mar 31, 2023 | 4.28 Bn |
| Dec 31, 2022 | 4.53 Bn |
| Sep 30, 2022 | 4.68 Bn |
| Jun 30, 2022 | 4.69 Bn |
| Mar 31, 2022 | 5.03 Bn |
| Dec 31, 2021 | 4.74 Bn |
| Sep 30, 2021 | 4.69 Bn |